Hubbry Logo
Cervical capCervical capMain
Open search
Cervical cap
Community hub
Cervical cap
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Cervical cap
Cervical cap
Cervical cap
View on Wikipedia
from Wikipedia
Cervical cap
Oves brand cervical cap (discontinued)
Background
TypeBarrier
First use1838
Pregnancy rates (first year)
Perfect usePrentif, nulliparous: 9%
Prentif, parous: 26%
Typical usePrentif, nulliparous: 16%
Prentif, parous: 32%
Lea's Shield: 15%
Usage
ReversibilityImmediate
User remindersInserted with spermicide and left in place for 6 hours after intercourse
Clinic reviewFor fitting and subsequent replacements
Advantages and disadvantages
BenefitsFemcap may be left in place for 48 hours

The cervical cap is a form of barrier contraception. A cervical cap fits over the cervix and blocks sperm from entering the uterus through the external orifice of the uterus, called the os.

Terminology

[edit]

The term cervical cap has been used to refer to a number of barrier contraceptives, including the Prentif, Dumas, Vimule, and Oves devices.[1] In the United States, Prentif was the only brand available for several decades (Prentif was withdrawn from the U.S. market in 2005).[1] During this time, it was common to use the term cervical cap to refer exclusively to the Prentif brand.[2][3]

The Lea's Shield was a cervical barrier device which was discontinued as of 2008. Some sources use cervical cap to refer to the FemCap and Lea's Shield.[4][5] Other sources include FemCap in the term cervical cap, but classified the Lea's Shield as a distinct device.[1][6]

In the 1920s, cervical caps (and also diaphragms) were often just called pessaries.[7]

Cervical caps or conception caps have also been designed as a form of assisted reproductive technology, used to help people experiencing infertility.[8][clarification needed]

Medical use

[edit]

The effectiveness of cervical caps, as with most other forms of contraception, can be assessed two ways: method effectiveness and actual effectiveness. The method effectiveness is the proportion of couples correctly and consistently using the method who do not become pregnant. Actual effectiveness is the proportion of couples who intended that method as their sole form of birth control and do not become pregnant; it includes couples who sometimes use the method incorrectly, or sometimes not at all. Rates are generally presented for the first year of use. Most commonly the Pearl Index is used to calculate effectiveness rates, but some studies use decrement tables.

Contraceptive Technology reports that the method failure rate of the Prentif cervical cap with spermicide is 9% per year for nulliparous women (women who have never given birth), and 26% per year for parous women (who have given birth).[2] The actual pregnancy rates among Prentif users vary depending on the population being studied, with yearly rates of 11%[9] to 32%[2] being reported. An FDA-mandated study reported failure rates: Method rate 6.4% (vs. 4.6% for the diaphragm); Overall rate 17.4% (vs. 16.7% for the diaphragm).[10]

Little data is available on the effectiveness of the Oves cap and FemCap. The Oves manufacturer cites one small study of 17 users.[11] The FemCap website does not cite any data on the current version of the FemCap, but lists data for an older version which is no longer approved by the FDA.[12]

The effectiveness trial of Lea's Shield was too small to determine method effectiveness. The actual pregnancy rate was 15% per year. Of the women in the trial, 85% were parous (had given birth). The study authors estimate that for nulliparous women (those who have never given birth) the pregnancy rate in typical use may be lower, around 5% per year.[13]

Compared to other barrier methods

[edit]

In the 1920s, Marie Stopes considered the cervical cap to be the best method of contraception available.[14] Among barrier methods it provides the least intervention of a barrier surface between the penis and vagina resulting in natural contact between them.[15] Except for the Fem-Cap, it also leaves exposed all the vaginal wall so that the hormones, etc. in the seminal fluid of the man can be better absorbed by the woman.[16] The condom does not allow any absorption and the diaphragm exposes less area. However the condom does significantly reduce the likelihood of transmission of STDs.[17] The diaphragm is inserted painlessly. It does not stretch the vagina, nor does it interfere with internal muscle movements during sex, as it is too high up in the vagina. The tip of the penis might touch the cap depending on the position and the size of the penis. Note that what Stopes calls the "Dutch cap" is today known as the "diaphragm". A partial objection to this claim is that most women do not know how to voluntarily control these muscles, and that some size diaphragms do not stretch the vagina that much, especially if they are smaller in size [18][19] The cervical cap can be worn for a significantly longer period of time than the diaphragm. It can be inserted several hours before intercourse[20] and used successfully even if a woman's partner is drunk, etc.[21] Stopes concludes in favor of the cervical cap and "condemns" the diaphragm "for general use" [22]

Side effects

[edit]

Insertion and removal

[edit]

There are more complaints about difficulties in removal than difficulties with insertion.[23] Since suction holds the cap on, it may sometimes be difficult to remove unless one knows the tricks of removal. Marie Stopes wrote that for rim caps, one should work the tip of one's finger under the rim and pull with a jerk. The idea is to release suction before pulling hard. If one's fingers are too short (and/or the vagina too long), one can use an inserter (intended for diaphragms) or have one's partner do it.

Odor

[edit]

Since the cervical cap can be worn for longer periods of time than the diaphragm, it is more prone to develop odors which might begin to appear after three continuous days of wear.[24]

Types

[edit]
An illustration of a cervical cap and spermicidal cream
Cervical Cap

Several brands of caps were manufactured during the late 20th and early 21st centuries. They can be divided into two types: cavity rim caps, and other caps. Cavity rim caps adhere to the cervix, while other caps adhere to the vaginal walls around the cervix. However, the FemCap (the only cervical cap sold in the United States after 2008) adheres to both.

The cavity rim caps are Prentif, made of latex, and the disposable cap Oves, made of silicone. There are four sizes of Prentif: 22, 25, 28, and 31 mm. There are three sizes of Oves: 26, 28, and 30 mm. Unique among cervical caps, it adheres to the cervix by surface tension, rather than by suction.[1]

The other devices are the latex Dumas and Vimule, and the silicone FemCap, Lea's Shield, and Shanghai Lily. There are five sizes of Dumas: 50, 55, 60, 65, and 75 mm. There are three sizes of Vimule: 42, 48, and 52 mm. There are three sizes of FemCap: 22, 26, and 30 mm. There are four sizes of Shanghai Lily: 54, 58, 62, and 66 mm. Lea's Shield is manufactured in a single size. Unlike the other caps, Lea's Shield has a one-way air valve that helps it seal to the vaginal walls. The valve also allows the passage of cervical mucus. FemCap does not have such a valve and as such can be used to collect cervical mucus to support the Billings method.[25] Both Lea's Shield and FemCap have loops to assist in removal.[1]

Shanghai Lily is only available in China.[1] As of 2008, many of the other devices are no longer being manufactured: Prentif, Vimule, and Dumas have been discontinued.[26] Oves is only being sold as a conception cap, not as a birth control device.[citation needed] As of February 2009, FemCap was the only brand of cervical cap available in the United States.[27] FemCap is also available in the UK via the NHS on prescription and is often distributed free from Family Planning Clinics depending on the health authority.[28] Lea's Shield is only available as the German brand LEA contraceptivum.[29]

FemCap

[edit]

As of 2009, FemCap is the only brand available in the United States.[27] A new FemCap performed poorly in a user acceptability study, suggesting that the modifications increased coital pain or discomfort among female users and their male sex partners, and that the modifications did not improve ease of use overall.[30] However, FemCap users are still less likely to report such pain or discomfort than diaphragm users.[31]

Sponge covered cap

[edit]

A cap of the 1920s had a sponge permanently attached to the outer surface of the cap to hold a liquid spermaticide such as vinegar. It was not as easy to clean the cap when removed, due to the sponge part.[32]

2-part cap

[edit]

This cap of the 1920s (the "Mizpah") had a separate ring (rim) which went around the base of the cervix and was worn constantly. The cap portion (which has its own ring/rim) is snapped into the base ring for use. A criticism of it was that due to the groove in the base ring (so it could attach itself to the cap part) it could not be kept perfectly clean without removing it.[33]

Design

[edit]

Height of dome

[edit]

The dome of a cervical cap may be low with little air space between the dome and the cervix, or high with plenty of air space above the cervix enclosed under the dome. Stopes recommends the high dome type for the following reasons: 1. The high dome cap has room to store secretions from the uterus such as menstrual flow or flow possibly resulting from an orgasm. 2. The high dome cap is allegedly less likely to become dislodged should the penis push hard against the cervix.[34]

Rim

[edit]

Per Stopes (in the 1920s) they should be made of very pliable soft rubber which should not be wrinkled or withered.

Caps of the 1920s had three types of rims: solid rubber (like an o-ring), air-inflated rubber, or a spring encased in rubber. Stopes recommended the all-rubber cap with the solid rubber rim[35] There is also the question as to what is the best shape of the rim cross-section so that the penis is less likely to dislodge the cap by contact with the rim. Some caps such as the Prorace, advocated by Stopes, had a wide but flat thin rim so that a penis contact would tend to push the rim against the fornix which it is already resting against.[36]

Stopes recommendations

[edit]

The type of rim cap recommended by Stopes in the 1920s with a high dome of thin rubber was experimentally revived by Lamberts in England in 1981[37] and called the "test cap". It came in six sizes and its light weight meant that it was not as apt to be felt during sexual activity. It was not received well. Some thought it was too flimsy and more likely to dislodge, but Stopes had (in the 1920s) claimed just the opposite for this design, as did the director of a woman's health center who tried it out.

Process

[edit]

Fitting

[edit]
Position of a cavity rim cap. The actual size of the cap and cervix is significantly larger than shown.[38]

Individuals who wish to use a cervical cap are screened by a health care provider to determine if a cervical cap, or one brand of cap, is appropriate for them. If a cap is determined to be appropriate, the provider will determine the proper size. The user must be refitted after any duration of pregnancy, whether the pregnancy is aborted, miscarried, or carried to term through vaginal childbirth or caesarean section.[39]

Several factors may make a cap inappropriate for a particular woman. Women who have given birth may have scar tissue or irregularly shaped cervixes that interfere with the cap forming a good seal.[40] For some women, available sizes of cervical caps do not provide a correct fit. Also, cavity rim caps are not recommended for women with an anteflexed uterus.[41] In infrequent cases a woman may have a long vagina but short fingers and thus may not be able to place the cap correctly.[42] Overall, 80% to 85% of women who want caps can be fitted without issues.[43]

The rim cap should be such that the rim tucks into the fornix snugly and evenly so as to maintain good suction to hold it in place.[43]

In some countries, some devices (such as the Lea's Shield) are available without a prescription.[44]

Method of use

[edit]

The first step in inserting or removing a cervical cap is hand washing, to avoid introducing harmful bacteria into the vaginal canal.[39] The cap is inserted prior to sexual intercourse;[1] some sources state that insertion prior to sexual arousal decreases the risk of incorrect placement.[45] Most sources recommend the use of spermicide with the cap,[1][39][45][46] but some sources say spermicide use is optional.[40][47]

The cap remains in the vagina for a minimum of 6[45][46] to 8[1][47] hours after the last intravaginal ejaculation. It is recommended the cap be removed within 72 hours (within 48 hours is recommended in the U.S.).[1] Other than the disposable Oves cap, cervical caps can be washed and stored for reuse.[4] Silicone devices may be boiled to sterilize them.[48] Reusable caps may last for one[12] or two[39] years.

Some caps have a pull tab for removal, but it is claimed that pulling on it should not be done, since it the cap tends to adhere very tightly to the cervix. Instead, putting a finger under the rim and pulling with a jerk should easily detach it.[49]

Acceptability

[edit]

It was reported in the 1980s (during the cervical cap renaissance in the U.S.) that "women overwhelmingly preferred the cap to the diaphragm". On average, women also reported an increase in libido and frequency of sex.[50]

The Oves cap and the new version of the FemCap performed poorly in user acceptability studies.[51][30] The study on the FemCap concluded that the modifications to the FemCap significantly increased pain and discomfort among female users and their male sex partners, and that the modifications decreased acceptability of the device compared with the earlier version. The study of the Oves cap reported that few women indicated that they would use the cap in the future.

A pilot study conducted in Britain prior to the Lea's Shield's approval concluded that the Lea's Shield "may be acceptable to a highly select minority of women".[52]

As of 2002, the cervical cap was one of the least common methods of contraception in the United States. A 2002 study indicated that of sexually active American women, 0.6% are currently using either the cervical cap, contraceptive sponge, or female condom as their primary method of contraception, and fewer than 1% have ever used a cervical cap.[53]

History

[edit]

Ancient

[edit]

The idea of blocking the cervix to prevent pregnancy is thousands of years old. Various cultures have used cervix-shaped devices such as oiled paper cones or lemon halves. Others made sticky mixtures that included honey or cedar rosin, to be applied to the os.[54] The modern idea of a cervical cap as a fitted device that seals itself against the vaginal walls is of more recent origin; it emerged within the past century.

19th century

[edit]

In 1838, German gynecologist Friedrich Wilde created the first modern cervical cap by making custom-made rubber molds of the cervix for some of his patients.[54][55] These caps were probably short-lived, as uncured rubber degrades fairly quickly. An important precursor to the invention of more lasting caps was the rubber vulcanization process, patented by Charles Goodyear in 1844. In the 1840s or 1860s E.B. Foote, a U.S. physician claims to have invented the cervical cap but it's reported that his patent was denied since the device could be used for obscene purposes.[55] Foote claimed that his invention was "widely counterfeited". An occlusive pessary marketed in the United States as the "womb veil" seems to have been an early form of diaphragm or cervical cap.[56]

Over the next several decades, the cervical cap became the most widely used barrier contraceptive method in Western Europe and Britain. Although the diaphragm was always more popular in the United States than the cervical cap, the cap was also common.[57]

20th century

[edit]

Many designs were developed in the later 19th and early 20th century in various countries.[58] The Vimule cap became available as early as 1927. A book by Vimule and Co., published in 1898, advertises the Vimule Cap.[59] The Prentif brand cap was introduced in the early 1930s.[60] The Dumas cap was initially made of plastic, and was available by the 1940s.[61] Lamberts (Dalston) Ltd. of the UK manufactured these three cap types.[62] Other types of caps had stems to hold them in place in the cervix; some of the stems actually extended into the uterus. These stem pessaries became precursors to the modern intrauterine device (IUD).

Margaret Sanger brought cervical caps to the U.S. in the 1910s, but later on seemingly preferred the diaphragm, and never repudiated the cap. This may have been influenced by her visit to the Netherlands where the diaphragm (also known as the "Dutch Cap") reigned supreme.

Use of all barrier methods, but especially cervical barriers, dropped dramatically after the 1960s introduction of the combined oral contraceptive pill and the IUD. In 1976, the U.S. government enacted the Medical Device Regulation Act. This law required all manufacturers of medical devices to provide the United States Food and Drug Administration (FDA) with data on the safety and efficacy of those devices. Lamberts (Dalston) Ltd., the only manufacturer at that time, failed to provide this information, and the FDA banned the use of cervical caps in the United States.[57]

In the late 1970s, the FDA reclassified the cervical cap as an investigational device, and it regained limited availability.[63] Within a few years, the FDA withdrew investigational status from the Vimule cap, following a study that associated its use with vaginal lacerations.[57][64] In 1988, the then 60-year-old [65] Prentif cap gained FDA approval.[66] The feminist movement played a large role in re-introducing the cervical cap to the United States. One paper called its involvement at all steps of the FDA approval process "unprecedented".[67] This renewed interest in the cervical cap has been called "The cervical cap renaissance".[68]

Quality

[edit]

In the 1920s it was reported from England that "careless and hasty construction" could sometimes be found in many brands. Some caps had a seam in the dome (two parts of it were welded together making a seam) and the seam might be defective and even contain minute perforations. Also, the junction between the rim and the dome might be rough and difficult to clean. Caps that were seamless avoided the "seam" problem. It was suggested that caps should be inspected for possible defects by the user under a magnifying glass.[69]

[edit]

A cervical cap is very likely the contraceptive that maid Anna Bates buys for her mistress Lady Mary Crawley in the second episode of the fifth series of the period drama Downton Abbey. Mary Crawley is inspired by the book Married Love, from Marie Stopes.[70]

Bibliography

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Cervical cap

View on Grokipedia
from Grokipedia
The cervical cap is a reusable barrier contraceptive device consisting of a small, flexible cup typically made of rubber or that is inserted into the to fit snugly over the , creating a seal that mechanically blocks from entering the , often in conjunction with applied to its rim for added . Unlike larger vaginal barriers such as the diaphragm, the cervical cap is smaller, requires precise fitting to the individual's cervical dimensions, and can remain in place for up to 48 hours, allowing for multiple acts of intercourse without reapplication. Its effectiveness varies significantly by user parity: randomized controlled trials indicate that the Prentif model achieves pregnancy prevention rates comparable to the diaphragm (approximately 80-94% with typical use), performing better in nulliparous women due to stronger , whereas the FemCap shows reduced in parous women, with typical rates approaching 20-30% in some studies. Historically, cervical cap-like devices trace back centuries under principles of cervical occlusion, but modern iterations emerged in the early , with U.S. production from the to before regulatory approval in 1988, though widespread adoption has been limited by fitting requirements, potential for displacement or rare , and discontinued manufacturing of early models like Prentif. As a hormone-free option, it appeals to those seeking non-systemic contraception, yet empirical data underscore its inferiority to intrauterine devices or hormonal methods in real-world prevention, necessitating consistent use and proper insertion for optimal results.

Definition and Terminology

Definition

The cervical cap is a reusable barrier contraceptive device comprising a small, cup-shaped structure typically made of or latex-free rubber that adheres tightly over the to physically block from entering the . It functions by creating a mechanical seal via , supplemented by the application of inside the cap to immobilize or kill that may contact the barrier. This method differs from broader vaginal barriers like the diaphragm, as the cap is smaller, more rigid, and positioned directly on the rather than covering the . Insertion occurs manually into the prior to intercourse, with the device remaining in place for a minimum of six hours post-coitus to allow to act fully, though it can be left for up to 48 hours. Proper fit, determined by cervical and , requires assessment, particularly as postpartum changes may render it less suitable for women who have delivered vaginally. The cap's , often resembling a sailor's with a brim for stability, facilitates self-placement after initial training but demands verification of positioning to prevent dislodgement during use. As a non-hormonal option, the cervical cap offers on-demand protection without systemic effects, though its relies on consistent correct use and compatibility with individual . Historical variants have employed materials like rubber or plastic, but modern iterations prioritize biocompatible for durability and hypoallergenicity, with reusability extending over multiple cycles following sterilization.

Historical and Regional Terminology

The earliest documented reference to a device resembling the modern cervical cap appeared in 1838, when German gynecologist Frederick Adolphe Wilde described a rubber contraceptive fitted over the , which he termed a Cautchuk Pessarium (rubber ). This term reflected the broader historical use of "pessary" for intravaginal devices, encompassing both supportive and contraceptive applications, though modern usage distinguishes pessaries primarily for pelvic support from barrier contraceptives like the cervical cap. By the early 20th century, particularly in Britain and , alternative designations such as "vault cap" and "diaphragm cap" emerged to describe cup-shaped barriers adhering to the or directly to the via suction. Specific variants included the French-originated Dumas vault cap, marketed in and from the 1920s onward as a "Dumas Antigenture" type, and the Prentif cavity rim cap, which emphasized a rim design for retention. An antecedent device, the "womb veil," patented in the United States in 1863 by Edward Bliss Foote, functioned as a rubber occlusive precursor to both cervical caps and diaphragms. In the United States, cervical caps were commercially available from the to under brands like Products' rubber domes and the Surgical Instrument Research Laboratory's "Cervicaps," available in materials such as silver, chrome, and plastic across multiple sizes; sales often employed euphemisms like "" or "marriage hygiene" to circumvent laws restricting open discussion of contraception. Regionally, terminology varies: in the , the device is commonly called a "cap" or "contraceptive cap," as in the NHS designation for the silicone FemCap model. In French-speaking areas, it is known as cap cervicale or cape cervicale, reflecting direct translation and historical European manufacturing influences. The standardized English term "cervical cap" gained prominence post-World War II to differentiate the smaller, cervix-specific device from the larger vaginal diaphragm, aligning with clinical trials and regulatory approvals in the late 20th century.

Mechanism and Design

Mechanism of Action

The cervical cap operates as a mechanical barrier contraceptive by being inserted into the vagina and fitted snugly over the cervix, where it adheres via suction to cover the cervical os completely and prevent spermatozoa from entering the uterus. The device's rim or groove creates a vacuum seal against the exocervical surface, ensuring physical obstruction of sperm migration through the endocervical canal. Prior to insertion, a spermicidal agent, such as , is applied to the inner dome and rim groove, transforming the cap into a that immobilizes or lyses upon contact, thereby providing a dual mechanical-chemical barrier without altering , fertilization post-barrier breach, or implantation processes. depends on correct placement, which requires the cap to be pushed deep into the until the is centered under the dome, verifiable by touch. Design variations influence suction mechanics: the Prentif cap employs a firm, round rim with a groove for airtight adhesion directly to the , while the FemCap, made of , uses a sailor-hat shape with a vaginal fornix-fitting rim and a peripheral brim for additional wall adherence. The cap must remain for a minimum of six hours after intercourse to maximize spermicidal action but should not exceed 48 hours to mitigate risks of bacterial overgrowth or .

Key Design Features

The cervical cap is a small, - or cup-shaped barrier device constructed from soft, flexible or rubber, engineered to fit snugly over the and prevent from entering the . Its compact size, typically measuring about 1.25 inches in length, distinguishes it from larger barriers like the diaphragm, allowing precise coverage of the alone rather than surrounding vaginal areas. Central to its design is a dome deep enough to fully enclose the , combined with a narrow groove or recessed brim along the inner rim that generates upon insertion, creating a seal against the cervical surface for retention. This mechanism enables the cap to adhere reliably, often remaining in place for 48 to 72 hours after fitting. Many models incorporate a short stem, loop, or extending from the dome for user-controlled removal, minimizing the risk of accidental dislodgement or trauma during extraction. application to the outer rim is , as the design facilitates accumulation at the edges where the chemical agent immobilizes potential escapees. Variants like the FemCap feature a sailor's profile with a flared brim to enhance stability, particularly for users with cervical changes post-partum, while maintaining the core suction-based adherence. construction predominates in contemporary designs to reduce risks associated with alternatives.

Types and Variants

Cervical caps are distinguished primarily by their material, , and sizing to accommodate anatomical variations. Traditional variants include firm rubber caps, which provide structural rigidity for secure placement, and soft rubber caps, offering greater flexibility but requiring precise fitting by medical professionals to ensure . The Prentif Cavity-Rim Cervical Cap, a latex-based model with a cavity-rim for enhanced against the cervix, was widely used and demonstrated contraceptive effectiveness comparable to the diaphragm in clinical trials conducted in the 1990s, though it was discontinued in the United States by 2003 due to manufacturing challenges. The FemCap represents a contemporary variant, approved by the FDA in , featuring a dome-shaped structure that covers the and extends into the vaginal fornices for improved retention and reduced urethral pressure compared to earlier models. Available in three sizes—22 mm, 26 mm, and 30 mm—it is fitted based on cervical diameter and post-partum status, with the smallest size designated for nulliparous women and larger ones for those who have given birth vaginally. However, studies indicate the FemCap's effectiveness is lower than the diaphragm, with higher typical-use failure rates reported in comparative trials. Historically, cervical caps evolved from 19th-century prototypes, with early forms made of materials like rubber or metal, but modern usage prioritizes silicone to minimize latex sensitivities prevalent in up to 10% of users. In regions outside the U.S., such as , variants like the vimule cap—a soft, reusable model—continue to be available, though empirical data on their comparative performance remains limited compared to U.S.-approved devices. All variants require application for optimal sperm-blocking action, with designs emphasizing a tight seal to prevent dislodgement during intercourse.

Efficacy and Effectiveness

Empirical Effectiveness Rates

The Prentif cervical cap, one of the most studied variants, exhibited a first-year of 8.4 pregnancies per 100 women in a 1982 multicenter involving consistent users followed via life-table , with 25 pregnancies observed across 3,243 woman-months of exposure; this included 11 method failures and 14 user-related failures such as dislodgement or improper placement. A subsequent Cochrane review of randomized controlled confirmed the Prentif cap's as equivalent to the diaphragm, reporting non-significant Peto odds ratios for of 1.24 (95% CI 0.89-1.74) across 1,153 participants in a trial spanning 6-42 months, though indicated approximately twice the among parous women (30% relative rate) compared to nulliparous women (15% relative rate). In contrast, the FemCap showed inferior performance in a 1999 randomized of 841 women followed for 28 weeks, with a Kaplan-Meier cumulative 6-month ratio of 1.7 versus the diaphragm and a significant Peto of 1.77 (95% CI 1.02-3.07), yielding no clinical equivalence; parity did not significantly influence outcomes in this study. Aggregated peer-reviewed estimates place perfect-use failure rates for cervical caps at 10-13% in the first year, reflecting consistent correct application with , while typical-use rates, incorporating inconsistent or erroneous application, range from 17-23%, with higher failures (up to 40% in some parous cohorts) attributed to dislodgement, suboptimal fit, or omitted . These rates derive from Pearl Index calculations in controlled settings and may overestimate real-world efficacy due to toward motivated participants; observational data from private practice settings report similar or slightly higher failures (e.g., 16.9 per 100 woman-years), underscoring the method's sensitivity to user adherence and anatomical factors like cervical shape post-partum. No large-scale contemporary trials post-2000 provide updated empirical benchmarks, as cervical cap use has declined amid alternatives, but historical data consistently highlight lower reliability than hormonal methods while matching other barriers under ideal conditions.

Factors Affecting Efficacy

The efficacy of the cervical cap is highly dependent on accurate fitting by a healthcare provider, as improper size relative to cervical dimensions can lead to inadequate seal and leakage. Clinical studies indicate that the cap must conform precisely to the cervical contours to maintain , with misfitting contributing significantly to method failure rates exceeding 10% in the first year under typical use. User technique plays a critical role, including correct insertion, verification of placement via or self-examination, and avoidance of displacement. Accidental dislodgement during intercourse, particularly vigorous activity, accounts for a substantial portion of failures, as the cap's rim can shift if not securely positioned beforehand. In one analysis of data, dislodgement was identified as the primary mechanical cause of method failure, elevating risk beyond perfect-use estimates of 6-9%. Parity influences outcomes, with parous women experiencing higher failure rates—up to 29% in typical use—due to cervical softening and altered shape post-childbirth, which impairs the cap's retention compared to nulliparous women (around 14% typical failure). Concurrent use of enhances efficacy by immobilizing that may bypass the barrier, and its omission correlates with increased discontinuation and inconsistent application, indirectly raising failure probabilities. Consistency of use differentiates perfect-use efficacy (3-8% first-year failure) from typical-use rates (12-26%), where lapses such as forgetting insertion or inadequate replenishment predominate. The cap's design permits protection for multiple coital acts over 48 hours without reinsertion, potentially mitigating some user errors if initial placement is correct, unlike methods requiring per-act reapplication.

Comparisons to Other Contraceptive Methods

Versus Diaphragm

The cervical cap and diaphragm are both reusable barrier contraceptives that require fitting by a healthcare provider and use with to block sperm from reaching the , but they differ in design, placement, and duration of use. The cervical cap is a smaller, thimble-shaped dome (typically 28-32 mm in diameter) that adheres directly to the via , sealing it more precisely, whereas the diaphragm is a larger, shallower dome (65-85 mm) that domes over the and rests against the vaginal walls and pubic bone for broader coverage. This allows the cervical cap to remain in place for up to 48-72 hours after intercourse, compared to the diaphragm's recommended maximum of 24 hours, reducing the need for immediate post-coital removal and potentially lowering disruption during extended sexual activity. Both methods fail primarily due to , such as improper insertion, dislodgement, or inconsistent application, with typical-use failure rates ranging from 12-29% annually depending on the device and user parity. In direct comparisons from randomized controlled trials, the Prentif cervical cap demonstrated pregnancy prevention efficacy comparable to the diaphragm (cumulative gross pregnancy rates of 11.3% vs. 13.1% at 12 months in one study of 311 women), while the FemCap showed lower (17.2% vs. 10.0% at 6 months in a of 330 women), attributed to higher dislodgement rates in nulliparous users. Effectiveness varies by parity: for women who have given birth vaginally (parous), the cervical cap achieves typical-use failure rates of 26% without alone but improves to 14-29% with , outperforming the diaphragm's 20% rate in some cohorts due to better cervical fit post-childbirth; nulliparous women, however, experience higher cap failure (up to 29%) from insertion challenges and suction loss. Diaphragm benefits from its larger size, which provides mechanical stability against movement, but requires reapplication of for multiple acts within 6 hours, unlike the cap's sustained seal. User experience and acceptability differ notably, with the cervical cap often rated more comfortable for long-term wear due to its minimal profile and lack of pressure on the or —addressing a common diaphragm complaint linked to urinary tract infections (UTIs) from compression (incidence 10-20% higher with diaphragms in observational data). However, the cap's smaller size and precise fitting demand greater manual dexterity for and removal, leading to higher discontinuation rates (up to 30% at 12 months vs. 20% for diaphragms) among beginners or those with short fingers. Both carry similar low risks of allergic reactions to or (1-5% incidence), vaginal irritation, or rare if left beyond recommended times, but neither protects against sexually transmitted infections.
AspectCervical CapDiaphragm
Size and PlacementSmall dome on cervix (suction seal)Larger dome over cervix and vagina
Max Wear Time48-72 hours post-intercourse24 hours post-intercourse
Typical Failure Rate (with spermicide)14-29% (lower in parous women)12-20%
UTI RiskLower (less urethral pressure)Higher (from compression)
Insertion DifficultyHigher (precise fit required)Lower (broader coverage)
Data derived from systematic reviews of trials involving over 1,000 participants.

Versus Other Barrier Methods

The cervical cap shares similarities with other barrier methods, including the male condom, , , and , in relying on physical or chemical obstruction of without hormonal interference. However, it differs in requiring professional fitting and typically being used with , while offering reusability for multiple cycles if properly maintained. Unlike condoms, the cervical cap provides no barrier against sexually transmitted infections (STIs), as it covers only the rather than the entire vaginal or penile surface. Efficacy comparisons reveal the cervical cap's typical-use failure rate of about 22% (pregnancies per 100 women in the first year), which is higher than the male condom's 13% but comparable to the contraceptive sponge's 20-32% (varying by parity) and spermicides' 28%. Perfect-use rates improve to 6-9% for nulliparous women using the cap, though they rise to 26% for parous women, reflecting challenges in fit and retention post-childbirth; male condoms achieve 2% perfect-use efficacy regardless of parity. Female condoms have typical-use failure rates around 21%, similar to the cap but with added STI protection due to broader coverage.
MethodTypical-Use Failure RatePerfect-Use Failure RateSTI Protection
22%6-26% (nulliparous to parous)No
Male Condom13%2%Yes
21%5%Yes
20-32% (nulliparous to parous)9-20%No
28%18-19%No
Data derived from aggregated clinical estimates; actual rates vary by user adherence and anatomy. In terms of usability, the cervical cap requires insertion 30-60 minutes prior to intercourse and can remain in place up to 48 hours, allowing spontaneity without per-act application, unlike single-use condoms or sponges that demand immediate pre-coital placement and removal within hours. Spermicides alone offer no mechanical barrier, leading to higher displacement risks. However, the cap's insertion demands practice and risks dislodgement (up to 10-15% of cases in studies), potentially exceeding the male condom's simpler rollout method, which has a 1-2% breakage rate but avoids fitting visits. Cost-wise, after initial fitting ($150-300), the cap's reusability (up to 2 years) undercuts ongoing expenses for disposables like condoms ($0.50-2 each) or sponges ($15-20 per unit), though remain cheapest upfront. Side effects are minimal across methods but include allergic reactions to spermicide (common to cap, sponge, and spermicides) and rare risks with prolonged cap or sponge retention.

Versus Hormonal Contraceptives

The cervical cap demonstrates substantially lower compared to hormonal contraceptives. For nulliparous women, perfect use yields approximately 86% , declining to 71% for parous women, while typical use is 71-82% overall, influenced by factors such as correct insertion and application. In contrast, combined oral contraceptives achieve 99% with perfect use and 91% with typical use, owing to their systemic suppression of and endometrial changes, though reliant on consistent adherence.
MethodPerfect Use EffectivenessTypical Use Effectiveness
Cervical Cap71-86%71-82%
Combined Oral Contraceptives99%91%
A primary distinction lies in health risks: the cervical cap avoids systemic hormonal exposure, eliminating elevated risks of (relative risk ~1.2 for current users) and (2- to 4-fold increase with estrogen-containing formulations), which persist even with modern low-dose pills. Hormonal methods, however, provide non-contraceptive benefits, including reduced incidence of ovarian and endometrial cancers (up to 50% lifetime risk reduction with long-term use). The cap's side effects remain localized, such as spermicide-induced vaginal irritation or urinary tract infections (reported in up to 20% of users), without broader metabolic, mood, or disruptions observed in 10-30% of hormonal users. Fertility returns immediately upon discontinuation of the cervical cap, mirroring hormonal methods' reversibility but without potential post-use cycle irregularities from suppression. For women prioritizing avoidance of exogenous hormones—due to contraindications like with aura or personal history of thrombotic events—the cap serves as a viable, user-controlled alternative, albeit demanding manual skill and pre-coital preparation that reduces spontaneity relative to daily or long-acting hormonal options. Neither method protects against sexually transmitted infections.

Usage and Fitting

Professional Fitting Process

The professional fitting process for a cervical cap begins with a consultation between the patient and a healthcare provider, such as a gynecologist or clinician, to review medical and obstetric history. This assessment determines eligibility and selects the appropriate device size, as cervical caps like the FemCap are available in three sizes—Pearl (22 mm) for those never pregnant, Sapphire (26 mm) for those pregnant but without labor, and Emerald (30 mm) for those who have experienced labor—based on parity rather than custom measurement. Contraindications, including history, significant , or a flat , are evaluated to ensure suitability. A is typically performed using a speculum to visualize the , confirming its size, shape, position, and absence of abnormalities such as lesions or that could impair fit or increase risks like dislodgement. Unlike diaphragms, modern cervical caps like FemCap do not require trial insertion of sample sizes during the visit, as relies on historical criteria rather than direct measurement. The provider then issues a prescription, which is necessary for purchase, and demonstrates proper insertion, removal, and application using a model or instructional tools to verify comprehension. Post-fitting, providers counsel on usage guidelines, such as inserting the cap up to 48 hours before intercourse and leaving it in place for at least six hours afterward, along with recommendations for STI screening and use if needed. Refitting is advised after significant anatomical changes, such as , , or weight fluctuations exceeding 10 pounds, typically requiring a repeat 8-10 weeks postpartum. This process ensures the device's efficacy, reported at 96-98% with perfect use, while minimizing complications.

Insertion and Removal Methods

The insertion of a cervical cap begins with thorough using and water to maintain . Approximately one teaspoon of is applied: a small amount inside the dome, spread along the outer rim, and additional in the groove between the rim and dome to enhance contraceptive efficacy. The user then assumes a comfortable position, such as , lying down, or standing with one foot elevated on a low stool, to facilitate access to the . To insert, the are separated with one hand while the cap is folded or squeezed between the thumb and forefinger of the other hand. The folded cap is gently pushed into the with the dome and removal strap facing downward and the longer edge of the brim entering first, advancing it until it seats over the . Proper placement is verified by inserting a finger to feel that the is fully covered by the dome, the rim adheres snugly around the cervical base, and gentle tugging confirms without slippage. The cap can be inserted up to six hours prior to intercourse, and practice under professional guidance is recommended to master the technique and ensure consistent correct use. Removal is performed after the cap has remained in place for at least six hours following the last act of intercourse, but no longer than 48 hours total to minimize infection risk. The user squats or lies in a comfortable position, locates the removal strap or rim with the fingers, and presses upward against the dome to break the suction seal. The cap is then gently tilted and pulled out by hooking a finger under the rim or strap, avoiding forceful tugging to prevent discomfort or injury. Post-removal, the cap is washed with mild soap and warm water, inspected for damage such as cracks or tears, air-dried, and stored in a cool, dry place away from extreme temperatures. For subsequent intercourse while the cap remains in situ, additional spermicide is applied without removal using an applicator.

Duration and Maintenance Guidelines

The cervical cap must remain in place for a minimum of six hours after the last act of intercourse to allow sufficient time for to immobilize sperm. It can be inserted up to six hours prior to intercourse but should not exceed a total wear time of 48 hours from insertion to prevent risks such as or vaginal irritation. Guidelines specify removal within this timeframe, with no use recommended during , unusual , or signs of . After removal, the device requires immediate cleaning to maintain and integrity: wash thoroughly with mild or and water, rinse well under , and allow to air dry completely. Users should inspect the cap before and after each use for tears, holes, or deformities, discarding it if damage is detected. Avoid oil-based products like during cleaning or application, as they can degrade the material. For storage, place the dried cap in its provided plastic case in a cool, dry environment away from extreme temperatures or direct , such as not leaving it in a . Periodic professional refitting is advised, particularly after , weight changes, or cervical procedures, to ensure proper seal. With adherence to these protocols, including repeated washing and exposure, the cap supports a use lifespan of up to two years for models like the FemCap, though some guidelines recommend annual replacement.

Side Effects and Health Risks

Common Side Effects

Vaginal irritation represents the most commonly reported side effect associated with cervical cap use, often resulting from contact with spermicide rather than the device itself. This irritation can manifest as soreness, redness, or discomfort in the vaginal area, affecting a notable portion of users due to the chemical composition of nonoxynol-9 spermicides, which disrupt vaginal mucosa to immobilize sperm. An elevated risk of urinary tract infections (UTIs) has been observed among cervical cap users, potentially linked to the device's pressure on the or bacterial introduction during insertion. Clinical observations indicate this occurs more frequently than with non-barrier methods, though exact incidence varies by user and . Allergic reactions to in certain cap models or to spermicide components can cause localized itching, swelling, or , though alternatives mitigate latex sensitivity. Vaginal or abnormal discharge may arise if the cap remains in place beyond the recommended 48 hours, fostering bacterial overgrowth. Large-scale clinical trials report no severe gynecologic complications from routine use, with minor issues like transient discomfort or odor resolving upon discontinuation or proper . User surveys corroborate these findings, emphasizing that side effects are typically self-limiting and less prevalent than with hormonal alternatives.

Serious Health Risks

The primary serious health risk associated with cervical cap use is (TSS), a rare but potentially life-threatening bacterial caused by toxin-producing strains of or , which can proliferate in the vaginal environment if the device is left in place beyond recommended durations. TSS symptoms include sudden high fever exceeding 102°F (38.9°C), sunburn-like rash, muscle aches, vomiting, diarrhea, and , progressing to organ failure if untreated; mortality rates for menstrual-related TSS have historically reached 3-5% with prompt antibiotic therapy. Although no confirmed cases of TSS directly attributable to cervical caps have been widely documented in peer-reviewed literature as of 2023, the risk mirrors that of other intravaginal barrier methods like diaphragms, arising from prolonged moisture and occlusion that foster anaerobic bacterial growth, particularly if inserted during or retained over 48 hours. To mitigate this, manufacturers and health authorities mandate removal within 48 hours maximum, avoidance during menses, and immediate medical attention for prodromal symptoms. Severe cervical or vaginal infections, including exacerbated cervicitis or pelvic inflammatory disease (PID) in susceptible users, represent another category of serious risks, potentially leading to infertility, ectopic pregnancy, or chronic pelvic pain if bacterial ascension occurs due to microtrauma from insertion/removal or spermicide irritation. Empirical data from clinical evaluations indicate such events are infrequent, with one retrospective study of 130 users reporting no significant infectious complications over 12 months, though contraindications exist for those with prior PID or abnormal Pap smears to prevent aggravation. Rare instances of cervical trauma, such as lacerations or ulcerations during fitting or displacement, have been noted in comparative trials, though incidence appears lower than with diaphragms (odds ratio 0.31 for cap users). Hypersensitivity reactions to the or components (in older models) or can escalate to in sensitized individuals, manifesting as widespread urticaria, , or respiratory distress, though population-level anaphylaxis rates remain below 0.1% based on barrier method data. Users with known allergies are advised against use, and prospective monitoring in trials has shown minimal systemic adverse events overall. Long-term use may correlate with transient abnormal Papanicolaou (Pap) smears in some cohorts, potentially masking or mimicking precancerous lesions, necessitating regular ; however, causality is not firmly established and resolves upon discontinuation in reported cases.

Empirical Data on Incidence

In clinical trials, serious health risks such as have not been reported with cervical cap use, despite the theoretical possibility due to extended wear times of up to 48 hours. A multicenter trial of the cavity-rim cervical cap involving 3,433 women from 1981 to 1988 documented no serious medical or gynecologic complications over extended follow-up. Common adverse events are primarily minor and related to local or device issues. In the same trial, more than 20% of users experienced dislodgment during or after intercourse, malodor, or partner discomfort, though these did not lead to discontinuation in most cases. use, required with most caps, contributes to risks like vaginal and urinary tract infections (UTIs), but rates are comparable to other barrier methods. A Cochrane systematic review of randomized controlled trials comparing cervical caps to diaphragms reported infection rates per 100 woman-years for the Prentif cap as follows: vaginitis (29.7), bacterial vaginosis (39.7), candidiasis (39.5), and UTIs (14.8), with no significant differences versus diaphragms. Prentif users showed lower odds of vaginal ulcerations or lacerations (OR 0.31, 95% CI 0.14–0.71) but higher rates of cervical cytologic changes from Class I to III (OR 2.31, 95% CI 1.04–5.11). For the FemCap, a pivotal FDA-reviewed study of 346 women found the following incidence of common events: vaginal candidiasis (18.8%), unspecified vaginitis (9.8%), blood in the device (9.0%), and UTIs (7.5%). Compared to diaphragms, FemCap users had reduced UTI odds (OR 0.59, 95% CI 0.36–0.95) but increased blood in the device (OR 2.29, 95% CI 1.27–4.14), with no differences in Papanicolaou smear abnormalities or other infections. Minor mucosal changes like petechiae (up to 22.6% at 2 weeks) and erythema (up to 7.5%) were noted in smaller fitting studies but resolved without intervention.
Adverse EventIncidence in FemCap Pivotal Study (N=346)Comparison to Diaphragm (OR, 95% CI)
Vaginal 18.8%No significant difference
9.8%No significant difference
Blood in Device9.0%Higher (2.29, 1.27–4.14)
UTI7.5%Lower (0.59, 0.36–0.95)

Acceptability and User Experience

User Satisfaction Surveys

A 1983 study of 76 women fitted with the cervical cap over one year reported 89% satisfaction with the method, though continuation was 51% and users noted issues such as , cramping, and . A 1984 retrospective survey of 56 respondents from 130 fitted users, primarily young and highly motivated women, found 84% satisfaction and a 75% continuation rate for at least three months, with no major health risks but occasional dislodgement contributing to inconsistent use. In a 1986 prospective study of 516 follow-up users from 617 fitted, many expressed high satisfaction, attributing it to the device's non-hormonal profile, yet acceptability was tempered by frequent reports of dislodgement, user or partner discomfort, insertion/removal challenges, and . Larger comparative trials highlighted practical barriers to sustained satisfaction. The 1986 Bernstein trial of the Prentif cap (1,153 analyzed women) showed higher discontinuation than the diaphragm due to effectiveness concerns (6-month rate ratio 3.0), though method dislike was less common (rate ratio 0.3); completion rates were 34% for the cap versus 28% for the diaphragm. The 1999 Mauck trial of the FemCap (748 analyzed) reported 37% discontinuation versus 29% for the diaphragm (6-month rate ratio 1.2, not significant), with cap users less likely to continue post-trial (odds ratio 0.47) or recommend it (odds ratio 0.48), primarily citing dislodgement (31% versus 6%, odds ratio 5.46) and removal difficulties (odds ratio 3.14). A 2002 short-term study of the Oves cap involving 20 women across 84 uses found initial difficulties with fitting (50% in first three uses) and removal (60% in first three, nearly 50% later), leading few participants to express interest in future use despite satisfaction with alternative methods. These findings, drawn from peer-reviewed trials, indicate initial satisfaction often exceeds 80% in smaller, motivated cohorts but declines with real-world challenges like fit and maintenance, with limited recent large-scale surveys reflecting the method's niche adoption.

Discontinuation Reasons

Discontinuation of the cervical cap often stems from method-related failures, including and device dislodgement during intercourse. In a clinical study of 499 women using the Prentif cervical cap exclusively in private practice, accounted for a gross discontinuation rate of 19.1 per 100 women, while dislodgement contributed 12.9 per 100, marking these as the primary reasons for cessation over a one-year period. These failures highlight challenges in maintaining proper fit and under varying anatomical conditions or . User dissatisfaction drives a substantial portion of discontinuations, with rates exceeding those of many other barrier methods. Among women relying on reversible contraception, the cervical cap exhibited one of the highest proportions of dissatisfaction-related discontinuations at 52%, attributed to factors such as insertion difficulties, discomfort, and perceived messiness from required spermicide application. Overall, approximately 46% of users reported ever discontinuing a method due to dissatisfaction, with cervical caps correlating strongly with complaints over ease of use and reliability compared to alternatives like oral contraceptives. Anatomical changes, particularly postpartum cervical alterations, frequently necessitate discontinuation due to compromised fit. Prentif cap users experienced a six-month cumulative discontinuation rate from cervical changes 1.8 times higher than diaphragm users in comparative trials, as the cap's smaller size and reliance on precise cervical conformity amplify sensitivity to such shifts. Spermicide-associated irritation or allergic reactions further contribute, though less dominantly, prompting switches to non-spermicide-dependent options. General discontinuation rates for the cap hover around 27% within the first year, aligning with barrier method trends but underscoring the need for user dexterity and consistent application.

Demographic and Cultural Factors

The cervical cap's suitability and adoption vary significantly by parity, with substantially higher effectiveness among nulliparous women (perfect use of 9% per year) compared to parous women (26% per year), due to anatomical fit challenges post-childbirth such as cervical lengthening and softening. This demographic factor leads clinicians to recommend the device primarily for women who have not given birth, limiting its appeal and use among mothers who comprise the majority of reproductive-age women seeking contraception. Socioeconomic status influences selection of barrier methods like the cervical cap, with higher-income and more educated women more likely to opt for them over hormonal alternatives, often prioritizing non-systemic options amid concerns over side effects. However, overall remains low across income levels—estimated at under 1% in national surveys—due to requirements for professional fitting, upfront costs (around $90 for the device plus clinic visits), and expenses, which deter low-income users despite coverage in some U.S. states since the 1980s. Cultural factors shape acceptability, particularly in contexts emphasizing female autonomy; during the 1970s-1980s U.S. feminist health movement, the cap gained niche support as a user-controlled, hormone-free alternative to the pill and IUD, aligning with self-examination practices promoted in texts like . Ethnic variations appear in clinic preferences, with non-Asian women in a 1990 California study showing lower favorability for the cap (13%) compared to oral contraceptives (50%), potentially reflecting broader cultural norms around method invasiveness or partner involvement. In conservative or taboo-laden settings, self-insertion may reduce uptake due to discomfort with genital manipulation, though empirical data on non-Western cultures is limited, with adoption near-zero in surveys from regions like where modern barrier methods register under 1%.

Historical Development

Ancient and Early Uses

The earliest documented precursors to the cervical cap appear in ancient Egyptian medical texts dating to approximately 1850 BCE, where women inserted vaginal pessaries composed of crocodile dung mixed with or fermented gum to occlude the and provide a spermicidal barrier against entry into the . These disposable devices relied on the acidic properties of gum, which contains compounds similar to modern spermicides, for additional contraceptive efficacy, though their primary mechanism was mechanical blockage. In the Greco-Roman era, the physician Soranus of Ephesus (c. 98–138 CE) detailed a comparable method in his treatise On Midwifery and the Diseases of Women, recommending the insertion of a wool or linen block saturated with acidic substances such as honey, vinegar, gum, myrtle juice, pomegranate, or cedar oil to cover and seal the cervical os, thereby preventing conception by impeding sperm passage. Soranus emphasized the device's fit against the cervix for effective occlusion, distinguishing it from broader vaginal barriers, and advised its use post-coitally or as a preventive measure, reflecting an empirical understanding of cervical anatomy despite limited materials available. Similar practices persisted across cultures into early modern periods; for instance, ancient Indian traditions involved cervical plugs of rock salt blended with to block the , while in 18th-century , recorded his female companions employing halved rinds—hollowed out and positioned over the —as an acidic, occlusive barrier, leveraging the fruit's for spermicidal effects alongside mechanical coverage. These organic, non-reusable approximations to the cervical cap demonstrate a consistent historical focus on cervical-specific barriers, though efficacy varied due to inconsistent fitting and material degradation, with no quantitative data on success rates from these eras.

19th Century Innovations

The modern cervical cap was first described in by German gynecologist Friedrich Wilde, who crafted custom rubber pessaries, known as Cautchuk Pessaria, by molding softened rubber directly to patients' cervixes for a tight seal over the cervical os to block spermatozoa. These devices represented a shift from earlier, less reliable occlusive methods, leveraging emerging rubber technology for improved durability and fit, though precise efficacy data from the era is absent. Wilde's innovation built on traditional European practices, such as disks, but introduced scalable production potential via rubber, predating widespread . The 1839 discovery of vulcanization by American inventor , patented in 1844, enabled harder, more elastic rubber that resisted degradation, facilitating further refinements in cervical cap design throughout the mid-1800s. Multiple variants of rubber caps emerged in and the , often requiring physician measurement for sizes ranging from 1 to 3 centimeters in diameter, with insertion via applicators or fingers to ensure adhesion via suction and sometimes cocoa butter as a . These innovations prioritized mechanical barrier efficacy over chemical adjuncts, though clinical trials were nonexistent, and user-dependent placement posed inherent risks of displacement. In America, physician Edward Bliss Foote advanced related barrier concepts in the 1860s with his "womb veil," a vulcanized rubber pessary intended to occlude the vaginal vault and cervix, functioning as a precursor to both caps and larger diaphragms; Foote sold thousands via mail order despite legal obscenity challenges under Comstock laws. Despite these developments, 19th-century caps saw limited diffusion outside elite medical circles, constrained by custom fitting needs, lack of standardization, and prevailing moral opposition to contraception, with European popularity exceeding American uptake but never achieving mass use.

20th Century Commercialization and Studies

Cervical caps saw limited commercialization in the United States during the early 20th century, with manufacturers such as Durex Products offering rubber dome variants and the Surgical Instrument Company producing metal models from the 1920s through the 1940s. Sales declined thereafter, overshadowed by the diaphragm and constrained by evolving medical regulations and material advancements favoring latex alternatives. In Europe, broader availability persisted, exemplified by the Prorace rubber cap developed by Marie Stopes for use in her 1921 family planning clinic. The Prentif Cavity-Rim Cervical Cap represented a key late-20th-century development, gaining U.S. (FDA) approval on May 23, 1988, following a regulatory review process that began in the amid heightened scrutiny of contraceptive devices. This approval marked the first formal U.S. market entry for a modern cervical cap design, though earlier variants like the Vimule cap had been studied and used internationally. Despite approval, commercial viability proved challenging, with Prentif and similar models like Vimule and Dumas failing to sustain widespread market presence due to user fit issues and competition from hormonal methods. Clinical studies in the mid-to-late focused on efficacy, , and comparative performance against diaphragms. A 1982 study of the Prentif cap, involving fittings from December 1977 to September 1979, assessed dislodgement as a primary failure cause and concluded the device matched diaphragms in and for suitable users. Another evaluation of 371 women reported a method of 3.7 per 100 woman-years, underscoring low when properly fitted and used with . Preliminary on the Vimule cap examined associated vaginal lesions, finding minimal adverse effects attributable to the device itself. These peer-reviewed assessments, drawn from controlled user experiences, affirmed the cap's occlusion principle as reliable for barrier contraception, though emphasizing the need for professional fitting to mitigate slippage.

Post-2000 Developments and Availability

In 2003, the U.S. Food and Drug Administration (FDA) approved the FemCap, a silicone-based cervical cap designed to address limitations of earlier latex models, such as allergic reactions and fitting challenges. The device features a dome-shaped structure with a removal strap on the exterior brim, available in three sizes (22 mm, 26 mm, and 30 mm) selected based on a woman's obstetric history: small for nulliparous women, medium for those with vaginal births, and large for cesarean sections. This second-generation design received Conformité Européenne (CE) marking for use in Europe, where it can remain in place up to 72 hours compared to 48 hours in the U.S. The FemCap is reusable for up to one year with proper cleaning and storage. Post-approval, the FemCap became the sole cervical cap commercially available worldwide with both FDA and CE approvals, filling the void left by discontinued predecessors like the Prentif cap. Limited clinical studies in the 2000s explored its integration with spermicides and potential for HIV/STI risk reduction, though evidence for the latter remains preliminary and focused more on diaphragms. No major new cervical cap designs have entered regulatory approval since, amid broader shifts toward long-acting reversible contraceptives, but the FemCap has sustained niche interest for its hormone-free profile. As of 2023, the FemCap requires a prescription from a healthcare provider for fitting and is obtainable at pharmacies, drugstores, or clinics , with many insurance plans covering it as a device. Availability is primarily limited to and ; it is not widely distributed in other regions due to regulatory and supply constraints. Usage remains low, categorized by U.S. reports as a less effective barrier method, reflecting challenges in provider training and consumer awareness.

Criticisms and Limitations

Effectiveness Limitations

The cervical cap exhibits moderate contraceptive efficacy, with perfect-use effectiveness of 86-91% and typical-use effectiveness of 71-80%, lower than many other barrier methods and hormonal options, resulting in typical-use pregnancy rates ranging from 14% to 29% annually, depending on user demographics and adherence. In perfect-use scenarios, where the device is correctly fitted, inserted prior to intercourse, and paired with while remaining in place for at least six hours post-coitus, failure rates approximate 6% to 9% for nulliparous women but rise to 9% to 28% for parous women due to anatomical changes in the and following , which compromise the cap's seal and retention. A key limitation stems from parity: studies consistently demonstrate substantially higher failure rates among women who have given birth vaginally, with one-year typical-use probabilities reaching 30% to 40% in parous users versus 15% to 20% in nulliparous users, attributed to cervical softening, elongation, and reduced tone that hinder proper suction and positioning. This disparity arises because the cap relies on a precise vacuum seal against the , which is more readily achieved in women without prior deliveries. User-dependent factors exacerbate inefficacy, including incorrect insertion (reported in up to 20% of attempts in clinical trials), accidental dislodgement during intercourse, and inconsistent application, all of which diminish barrier integrity and allow migration. Comparative trials, such as the 1986 multicenter study of the Prentif Cavity-Rim cap versus the diaphragm, revealed the cap's inferior performance, with cumulative gross pregnancy rates of 20% for the cap overall (15% nulliparous, 30% parous) against 17% for the diaphragm, highlighting the cap's greater sensitivity to placement errors and fit variability. Efficacy also declines without spermicide, as the cap alone provides incomplete spermicidal action, and reliance on nonoxynol-9 introduces risks of mucosal irritation that may indirectly promote failure through inflammation. Long-term studies indicate that discontinuation due to perceived unreliability further limits sustained use, with real-world adherence often falling short of trial conditions.

Practical and Accessibility Challenges

The cervical cap necessitates professional fitting by a clinician to match the device's size to the individual's cervical dimensions, a procedure that requires substantial time, effort, and expertise to avoid slippage or inadequate coverage, and may not suit women with unusual cervix shapes. Users frequently encounter challenges with self-insertion and removal, as the small, thimble-shaped device must be positioned precisely over the cervix using suction, requiring advance placement prior to intercourse, correct technique, and often repeated practice sessions for mastery. Improper technique can lead to dislodgement during intercourse, increasing failure risk, while the process may interrupt spontaneity if not pre-inserted. Additional practical hurdles include potential discomfort from the device or required , reduced efficacy for women who have given birth vaginally due to cervical changes that impair fit and seal, small risks of allergic reactions to the cap material or spermicide, and potential for vaginal infection if used improperly or during menstruation. Partner discomfort from the cap's presence has also been reported, sometimes necessitating removal post-intercourse to mitigate irritation. These factors contribute to a , with initial users particularly prone to errors in placement verification, which must be manually checked after insertion. Accessibility barriers stem primarily from the method's dependence on healthcare provider involvement for fitting and instruction, limiting uptake in underserved areas lacking trained clinicians. Costs typically range from $50 to $150 for the device, examination, and fitting, excluding ongoing spermicide expenses, which may deter low-income users without comprehensive insurance coverage. Unlike widely available over-the-counter options, the cervical cap's specialized nature results in sporadic distribution through college health services, midwifery practices, or select pharmacies, exacerbating disparities in regions with contraceptive service gaps.

Broader Debates on Barrier Methods

Barrier methods, including the cervical cap, are often debated in public health discussions for their lower typical-use effectiveness compared to hormonal contraceptives or long-acting reversible methods like intrauterine devices, with failure rates exceeding 20% in real-world scenarios due to user-dependent application errors such as improper insertion or timing. Proponents argue that barriers avoid systemic hormonal exposure, reducing risks like venous thromboembolism or potential long-term effects on mood and metabolism associated with combined oral contraceptives, making them preferable for individuals with contraindications to hormones or those prioritizing minimal physiological interference. Critics, however, contend that this efficacy gap contributes to higher unintended pregnancy rates, particularly among populations with inconsistent access to education or supplies, prompting recommendations for dual-method use combining barriers with more reliable options. A key distinction in these debates centers on sexually transmitted infection (STI) prevention, where male and female condoms provide substantial dual protection against both pregnancy and pathogens like HIV when used correctly—reducing HIV transmission risk by up to 80% with consistent application—whereas cervical caps and diaphragms offer negligible STI barrier due to incomplete coverage of vaginal surfaces and lack of external sheath protection. This limitation has fueled arguments for prioritizing condoms in STI-prevalent settings, such as among adolescents or in high-burden regions, while non-condom barriers like the cervical cap are positioned as supplementary for monogamous couples focused solely on contraception, though evidence shows limited added benefit against bacterial vaginosis or urinary tract infections from spermicide use. Accessibility and equity debates highlight barriers' over-the-counter availability for some types (e.g., condoms, spermicides) as an advantage over clinician-requiring methods like fitted cervical caps, yet persistent challenges include cost burdens for uninsured users— with one in five reproductive-age women reporting discontinuation due to affordability—and geographic barriers in rural or low-resource areas exacerbating disparities. advocates emphasize barriers' role in empowering user-controlled without medical intervention, aligning with preferences for non-invasive options in diverse cultural contexts, but systemic underpromotion relative to hormonal methods—potentially influenced by funding biases toward pharmaceutical-backed alternatives—raises concerns about informed choice. Overall, these methods are valued for their reversibility and absence of side effects but critiqued for demanding higher discipline, underscoring ongoing tensions between individual and population-level efficacy goals.

References

  1. https://medlineplus.gov/ency/presentations/100107_3.htm
  2. https://pubmed.ncbi.nlm.nih.gov/1990736/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC8719323/
  4. https://pubmed.ncbi.nlm.nih.gov/7018094/
  5. https://www.accessdata.fda.gov/cdrh_docs/pdf2/P020041b.pdf
  6. https://pubmed.ncbi.nlm.nih.gov/6551434/
  7. https://www.cdc.gov/contraception/about/index.html
  8. https://www.nichd.nih.gov/health/topics/factsheets/contraception
  9. https://my.clevelandclinic.org/health/articles/17979-cervical-cap
  10. https://www.merckmanuals.com/home/women-s-health-issues/family-planning/barrier-contraceptives
  11. https://www.sciencedirect.com/topics/medicine-and-dentistry/cervical-cap
  12. https://pubmed.ncbi.nlm.nih.gov/7099129/
  13. https://muvs.org/en/contraception/barriers/kawe-cap-pessary-id1385/
  14. https://collection.sciencemuseumgroup.org.uk/objects/co96323/rubber-vault-cap
  15. https://collection.sciencemuseumgroup.org.uk/objects/co96339/vault-cap-dumas-antigenture-type-london-and-paris-1920-1960
  16. https://catalog.nlm.nih.gov/discovery/fulldisplay/alma9910212913406676/01NLM_INST:01NLM_INST
  17. https://artsci.case.edu/dittrick/online-exhibits/history-of-birth-control/contraception-in-america-1900-1950/cervical-caps-and-diaphragms/
  18. https://www.nhs.uk/contraception/methods-of-contraception/contraceptive-diaphragm-or-cap/
  19. https://cervicalbarriers.org/cervical-caps/
  20. https://www.acog.org/womens-health/faqs/barrier-methods-of-birth-control-spermicide-condom-sponge-diaphragm-and-cervical-cap
  21. https://www.webmd.com/sex/birth-control/cervical-cap
  22. https://pubmed.ncbi.nlm.nih.gov/6813625/
  23. https://www.healthline.com/health/birth-control-cervical-cap
  24. https://www.sutterhealth.org/health/cervical-cap
  25. https://pubmed.ncbi.nlm.nih.gov/12519602/
  26. https://ebn.bmj.com/content/6/3/75
  27. https://www.sciencedirect.com/science/article/abs/pii/S0010782499000682
  28. https://www.cochrane.org/evidence/CD003551_cervical-cap-versus-diaphragm-birth-control
  29. https://pubmed.ncbi.nlm.nih.gov/7075188/
  30. https://pubmed.ncbi.nlm.nih.gov/8354373/
  31. https://www.drugs.com/medical-answers/birth-control-failure-rates-pearl-index-explained-3554953/
  32. https://www.sciencedirect.com/science/article/pii/0002937884907579
  33. https://www.glowm.com/section-view/heading/Use%2520and%2520Effectiveness%2520of%2520Barrier%2520and%2520Spermicidal%2520Contraceptive%2520Methods/item/384
  34. https://pubmed.ncbi.nlm.nih.gov/3881697/
  35. https://pubmed.ncbi.nlm.nih.gov/2664609/
  36. https://publications.aap.org/pediatrics/article/120/5/1135/71113/Contraception-and-Adolescents
  37. https://pubmed.ncbi.nlm.nih.gov/4067945/
  38. https://www.jogc.com/article/S1701-2163%2816%2939376-8/fulltext
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC3638203/
  40. https://www.guttmacher.org/journals/psrh/1999/03/contraceptive-failure-rates-new-estimates-1995-national-survey-family-growth
  41. https://www.health.harvard.edu/birth-control/methods/type/diaphragm-cervical-cap-sponge
  42. https://.ncbi.nlm.nih.gov/12519602/
  43. https://pubmed.ncbi.nlm.nih.gov/10592853/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC1875460/
  45. https://pubmed.ncbi.nlm.nih.gov/6616379/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC8406471/
  47. https://www.merckmanuals.com/professional/gynecology-and-obstetrics/family-planning/barrier-and-other-pericoital-contraceptives
  48. https://www.bedsider.org/birth-control/cervical_cap
  49. https://www.ncbi.nlm.nih.gov/books/NBK430882/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC9802294/
  51. https://pubmed.ncbi.nlm.nih.gov/29211679/
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC6714678/
  53. https://pmc.ncbi.nlm.nih.gov/articles/PMC11034842/
  54. https://www.ncbi.nlm.nih.gov/books/NBK235069/
  55. https://americanpregnancy.org/unplanned-pregnancy/birth-control-pills-patches-and-devices/cervical-cap/
  56. https://www.plannedparenthood.org/learn/birth-control/cervical-cap/what-are-benefits-cervical-caps
  57. https://www.naturalcycles.com/cyclematters/cervical-caps
  58. https://femcap.com/wp-content/uploads/2025/03/Clinicians-Instructions.pdf
  59. https://pubmed.ncbi.nlm.nih.gov/3405494/
  60. https://femcap.com/faq/
  61. https://femcap.com/clinicians/
  62. https://www.plannedparenthood.org/learn/birth-control/cervical-cap/how-do-i-use-cervical-cap
  63. https://www.hhs.nd.gov/cfs/family-planning/grantees/instructions-for-cervical-cap
  64. https://www.nhs.uk/contraception/methods-of-contraception/contraceptive-diaphragm-or-cap/side-effects-and-risks/
  65. https://www.sciencedirect.com/science/article/pii/S147176970180023X
  66. https://www.plannedparenthood.org/learn/birth-control/cervical-cap/how-safe-are-cervical-caps
  67. https://my.clevelandclinic.org/health/diseases/15437-toxic-shock-syndrome
  68. https://pubmed.ncbi.nlm.nih.gov/6643210/
  69. https://www.nhsinform.scot/healthy-living/contraception/cap/
  70. https://pubmed.ncbi.nlm.nih.gov/6702924/
  71. https://experts.arizona.edu/en/publications/the-cervical-cap/
  72. https://www.sciencedirect.com/science/article/pii/0010782486900156
  73. https://pubmed.ncbi.nlm.nih.gov/12419058/
  74. https://pubmed.ncbi.nlm.nih.gov/6509986/
  75. https://www.sciencedirect.com/science/article/pii/S0010782484800256
  76. https://www.sciencedirect.com/science/article/abs/pii/S0010782407002582
  77. https://pubmed.ncbi.nlm.nih.gov/17900435/
  78. https://www.tandfonline.com/doi/abs/10.1080/07399339009515900
  79. https://www.sciencedirect.com/science/article/abs/pii/S0010782400001293
  80. https://www.jogc.com/article/S1701-2163%2816%2934242-6/pdf
  81. https://notchesblog.com/2016/03/24/the-cervical-cap-in-the-feminist-womens-health-movement-1976-1988/
  82. https://pubmed.ncbi.nlm.nih.gov/2247590/
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC9590221/
  84. https://www.caya.us.com/the-evolution-of-womens-birth-control-ancient-to-modern-contraception/
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC8567737/
  86. https://www.naturalcycles.com/cyclematters/non-hormonal-birth-control-methods-through-history
  87. https://cervicalbarriers.org/cervical-barriers/
  88. https://time.com/archive/6712448/medicine-comeback-of-a-contraceptive/
  89. https://www.plannedparenthood.org/files/2613/9611/6275/History_of_BC_Methods.pdf
  90. https://www.pbs.org/wgbh/americanexperience/features/pill-timeline/
  91. https://link.springer.com/content/pdf/10.1007/978-3-642-73790-9_27.pdf
  92. https://www.jstor.org/stable/3104294
  93. https://wellcomecollection.org/stories/a-brief-history-of-contraception
  94. https://pubmed.ncbi.nlm.nih.gov/3417004/
  95. https://www.scivisionpub.com/articles/the-renaissance-of-hormonefree-barrier-contraception-and-development-of-femcap-hormonefree-contraception-1319.html
  96. https://www.sciencedirect.com/science/article/abs/pii/0010782482900269
  97. https://www.sciencedirect.com/science/article/pii/0010782482901433
  98. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P020041
  99. https://www.hhs.nd.gov/sites/www/files/documents/DOH%2520Legacy/Family%2520Planning/Grantees/Protocols/Contraceptives/CON%252013%2520-%2520Cervical%2520Cap.pdf
  100. https://pubmed.ncbi.nlm.nih.gov/12294213/
  101. https://opa.hhs.gov/sites/default/files/2025-08/2023-FPAR-national-summary.pdf
  102. https://www.plannedparenthood.org/learn/birth-control/cervical-cap/how-effective-are-cervical-caps
  103. https://cervicalbarriers.org/wp-content/uploads/2020/01/EOL_202final.pdf
  104. https://www.researchgate.net/publication/10957382_Cervical_Cap_versus_Diaphragm_for_Contraception
  105. https://www.clinician.com/articles/39328-10-years-out-cervical-cap-overcoming-barriers
  106. https://pmc.ncbi.nlm.nih.gov/articles/PMC7533104/
  107. https://www.sciencedirect.com/topics/medicine-and-dentistry/barrier-contraception
  108. https://pubmed.ncbi.nlm.nih.gov/8512049/
  109. https://www.cosrh.org/Common/Uploaded%2520files/documents/ceuguidancebarriermethodscontraceptionsdi.pdf
  110. https://www.kff.org/womens-health-policy/contraception-in-the-united-states-a-closer-look-at-experiences-preferences-and-coverage/
Add your contribution
Related Hubs
User Avatar
No comments yet.